Aquestive Therapeutics Q4 Earnings Call Highlights

Core Insights - Aquestive Therapeutics is preparing to resubmit its New Drug Application (NDA) for Anaphylm, an orally delivered epinephrine product, following a Complete Response Letter (CRL) from the FDA, with plans to conduct required studies [2][4][17] - The company reported a Q4 2025 revenue of $13.0 million, a decrease from $57.6 million in 2024, and a net loss of $31.9 million for the quarter [3][15] - The company is scaling its commercial preparations, increasing its sales representatives from 50 to 75, and expects to maintain a near cash-neutral position by the end of 2027 [4][6] Financial Performance - Q4 2025 revenue was $13.0 million, up from $11.9 million in Q4 2024, primarily due to higher manufacture and supply revenue [11] - Full-year 2025 revenue decreased to $44.5 million from $57.6 million in 2024, with a net loss of $83.8 million for the year [3][15][12] - SG&A expenses surged to $32.8 million in Q4 2025, driven by one-time legal costs and launch preparations, compared to $16.0 million in the prior-year quarter [14] Commercial Strategy - The company plans to launch Anaphylm with 75 sales representatives to enhance market reach, particularly in the allergist market [4][6] - Direct-to-consumer advertising will be pursued once the product achieves a reasonable market share, focusing on representative-driven outreach initially [7][8] - The launch timing post-FDA approval is expected to be within "zero to eight weeks," depending on supply chain readiness [8] Regulatory and Development Updates - The company is preparing for a Type A meeting with the FDA to ensure alignment on the studies required for NDA resubmission [1][2] - Upcoming pharmacokinetic (PK) studies will be the 12th trial for Anaphylm, incorporating FDA-requested elements [5] - The company is also pursuing regulatory applications for Anaphylm in Canada and the EU, with a focus on U.S. prioritization [17] Legal and Other Developments - A settlement was reached in a nine-year defamation lawsuit, described as cash neutral for 2026 [20] - The company opened an IND for AQST-108 and completed an initial safety study, with top-line data expected soon [19] - The FDA denied a citizen petition from a competitor, which the company views as a validation of its data package [20]